Table 2.
UC therapeutic strategies, disease course and complications
| Elderly (≥ 65 yrs) N = 94 |
Adults (40–64 yrs) N = 94 |
p value | |
|---|---|---|---|
| Therapy at the diagnosis | |||
| Mesalamine N (yrs, SD) | 55 (58.5) | 51 (54.8) | 0.612 |
| Steroids N (%) | 36 (38.3) | 31 (33.3) | 0.479 |
| Surgery at the diagnosis (%) | 5 (5.3) | 3 (3.2) | 0.479 |
| Follow-up | |||
| Surgery N (%) | 19 (20.4) | 8 (8.5) | 0.020 |
| Months to surgery, mean (SD) | 18.4 (34.1) | 24,87 (23.9) | 0.2903 |
| Mesalamine N (%) | 90 (95.7) | 86 (96.7) | 0.351 |
| Immunosuppressant N (%) | 10 (10.8) | 11 (12.1) | 0.837 |
| Biological therapy N (%) | 2 (2.1) | 20 (22) | < 0.0005 |
| Patients with one relapse or more, N (%) | 54 (57.5) | 52 (57.1) | 0.932 |
| Time to first relapse in months, mean (SD) | 19.04 (28.6) | 16,49 (22.9) | 0.5615 |
| Extraintestinal manifestations N(%) | 9 (9.6) | 18 (19.2) | 0.061 |
| Complications | |||
| Intestinal complications N (%) | 17 (18.1) | 5 (5.5) | 0.0007 |
| Systemic infections, N (%) | 28 (29.8) | 24 (25.5) | 0.514 |